# Systemic Rapamycin (Sirolimus) to Prevent In-Stent Restenosis Following Pulmonary Artery Stent Placement

> **NCT02365415** · PHASE2 · WITHDRAWN · sponsor: **Boston Children's Hospital**

## Conditions studied

- Peripheral Pulmonary Stenosis
- In-stent Stenosis

## Interventions

- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT02365415
- **Lead sponsor:** Boston Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-02
- **Primary completion:** 2018-04
- **Final completion:** 2018-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Unable to enroll appropriate patients
- **Last updated:** 2018-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02365415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02365415, "Systemic Rapamycin (Sirolimus) to Prevent In-Stent Restenosis Following Pulmonary Artery Stent Placement". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02365415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*